People

<p>The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an &#8220;on-the-ground&#8221;, local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors.</p>


Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.”

Transforming Life Sciences Innovation By Creating And Investing In Global Companies

Catalys Pacific

Home

Acquired

Acquired Archives - Catalys Pacific

IPO Archives - Catalys Pacific

Dr. Rajeev Venkayya

President, Global Vaccine Business Unit, Takeda

<p>HilleVax is a private, biopharmaceutical company launched by Takeda and Frazier focused on the development and commercialization of novel vaccine candidates. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.</p>


Advancing the Development of a Vaccine to Protect against Norovirus Infection

HilleVax - Catalys Pacific

HilleVax

Developing Innovative Treatments for LINE-1 associated Neurodegenerative Disease

Home

Creations

HilleVax

Transposon